UNSPSC 51281823: Mitoxantrone hydrochloride

This classification denotes an anthracenedione-derived antineoplastic agent, analgesic, and anthraquinone with the molecular formula C22H28N4O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6USW86RD0, chemically known as 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9ci) but more generally known as mitoxantrone hydrochloride, which bears US NIH Compound Identifier 4212.

UNSPSC 51281823 Mitoxantrone hydrochloride is a Commodity code with minimal recent state and local procurement activity directly mapped to this specific pharmaceutical. The recent opportunities tagged under this code do not involve mitoxantrone; instead, they span naloxone procurement, pharmacy benefit management infrastructure, medical and first aid supplies for emergency response, and multi-source generic pharmaceuticals distributed through cooperative purchasing alliances. State and local governments buying under pharmaceutical commodity codes typically source through group purchasing organizations, wholesaler networks, and cooperative procurement vehicles rather than direct manufacturer solicitations, and when specific drugs are procured, they are usually embedded within broader medical supply, pharmacy benefit, or emergency response contracts rather than isolated as single-product line items.

The issuing bodies in the recent opportunities include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), municipal fire departments (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). Geographic activity is scattered across Florida, Texas, Minnesota, and Oregon through cooperative procurement. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems posted June 30, 2026, with a July 26, 2023 response date; the Texas HHS Commission's RFI for direct-to-manufacturer prescription programs posted April 3, 2026; the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division, due March 13, 2026, with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products posted January 20, 2026, with a March 26, 2026 response deadline. The code shows little relevant recent activity tied to mitoxantrone specifically, suggesting limited direct-procurement demand or mislabeling of opportunities in the state and local system.